Subanalysis shows edoxaban benefits in cancer patients with VTE
This article was originally published in Scrip
Executive Summary
A new subanalysis of data from a large-scale Phase III study with Daiichi Sankyo's edoxaban shows benefits for the once-daily Factor Xa inhibitor over warfarin in terms of incidence of recurrent venous thromboembolism (VTE) and bleeding in cancer patients with VTE.